Skip to main content

Validation of pathology-based triage for the 21-gene recurrence score: a meta-analysis and qualitative synthesis of the Magee equations

In brief

Magee score below 18 spared 62% of tests with 96% negative predictive value

Across 13 studies involving 5,396 patients, a Magee score below 18 identified a group in whom the 21-gene recurrence score was below 26 in 96% of cases, potentially sparing 62% of tests. Variation in mitotic counting and Ki-67 scoring drove disagreements, so consistent pathology readings remain essential before using this approach to guide testing.

Journal
NPJ breast cancer (Q1)
Published
23 July 2026
Study design
Systematic review of cohort studies
Evidence level
Level 2, Moderate (CEBM 2a)
Authors
Thiti Susiriwatananont, Panuch Eiamprapaporn, Yaohua Ma, Phuwanat Sakornsakolpat, Jirawat Thanestada, Yi Liu, et al.
PMID
43020886
DOI
10.1038/s41523-026-01006-y

Why clinicians should know about it

  • Picked for Pathology and Forensic Medicine (top studies of the week, 15 November 2026): Routine histopathology triage, with interobserver variability in grading markers

Abstract

The 21-gene Oncotype DX (ODX) recurrence score (RS) is the standard for HR + /HER2- early breast cancer risk stratification, but prohibitive costs limit global accessibility. This meta-analysis of 13 studies (N = 5396) validates the Magee Equations (ME)-utilizing routine pathology (grade, ER/PR/HER2/Ki-67)-as a safe triage tool. For the TAILORx threshold (RS 26 or higher), a ME <18 yielded a pooled negative predictive value (NPV) of 0.96 (95% CI: 0.94-0.97) and a 62% test-sparing rate. At the RS 31 or higher threshold, NPV increased to 0.99. Qualitative synthesis identified inter-observer variability in mitotic counting and Ki-67 scoring as primary discordance drivers. While manual subjectivity remains a constraint, Magee-based triage provides a robust histopathological signal. Integrating AI-driven digital pathomics offers a transformative pathway to standardize interpretations and democratize precision oncology in resource-limited settings.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.